TYK2 and psoriasis vulgaris: In September 2022, the FDA-approved deucravacitinib, a first-in-class oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, after it demonstrated a favorable safety profile and greater efficacy than other available oral treatment options for plaque psoriasis.